239 related articles for article (PubMed ID: 28393558)
41. Forty-Three Fatalities Involving the Synthetic Cannabinoid, 5-Fluoro-ADB: Forensic Pathology and Toxicology Implications.
Boland DM; Reidy LJ; Seither JM; Radtke JM; Lew EO
J Forensic Sci; 2020 Jan; 65(1):170-182. PubMed ID: 31211877
[TBL] [Abstract][Full Text] [Related]
42. Respiratory failure in confirmed synthetic cannabinoid overdose.
Manini AF; Krotulski AJ; Schimmel J; Allen L; Hurd YL; Richardson LD; Vidal K; Logan BK
Clin Toxicol (Phila); 2022 Apr; 60(4):524-526. PubMed ID: 34499005
[TBL] [Abstract][Full Text] [Related]
43. Schedules of Controlled Substances: Extension of Temporary Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule I of the Controlled Substances Act. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2016 Feb; 81(24):6175-7. PubMed ID: 26859904
[TBL] [Abstract][Full Text] [Related]
44. Identification of 5-Fluoro ADB in Human Whole Blood in Four Death Cases.
Usui K; Fujita Y; Kamijo Y; Kokaji T; Funayama M
J Anal Toxicol; 2018 Mar; 42(2):e21-e25. PubMed ID: 29186561
[TBL] [Abstract][Full Text] [Related]
45. Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry.
Vikingsson S; Gréen H; Brinkhagen L; Mukhtar S; Josefsson M
Drug Test Anal; 2016 Sep; 8(9):950-6. PubMed ID: 26560240
[TBL] [Abstract][Full Text] [Related]
46. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine.
Helander A; Beck O; Bäckberg M
Clin Toxicol (Phila); 2015 Jun; 53(5):446-53. PubMed ID: 25881797
[TBL] [Abstract][Full Text] [Related]
47. Synthetic Cannabinoid Abuse Resulting in ST-Segment Elevation Myocardial Infarction Requiring Percutaneous Coronary Intervention.
Hamilton RJ; Keyfes V; Banka SS
J Emerg Med; 2017 Apr; 52(4):496-498. PubMed ID: 27769613
[TBL] [Abstract][Full Text] [Related]
48. Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB- CHMICA and MDMB-FUBINACA) Into Schedule I. Notice of Intent.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2016 Dec; 81(245):93595-9. PubMed ID: 28068047
[TBL] [Abstract][Full Text] [Related]
49. Do you feel it now? Route of administration and Δ
Wiley JL; Lefever TW; Glass M; Thomas BF
Neurotoxicology; 2019 Jul; 73():161-167. PubMed ID: 30953678
[TBL] [Abstract][Full Text] [Related]
50. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V
Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524
[TBL] [Abstract][Full Text] [Related]
51. Identification and Quantification of 5-Fluoro ADB and the 5-Fluoro ADB Ester Hydrolysis Metabolite in Postmortem Blood Samples by LC-MS/MS.
Seither JZ; Reidy LJ; Boland DM
J Anal Toxicol; 2020 Mar; 44(2):133-139. PubMed ID: 31274144
[TBL] [Abstract][Full Text] [Related]
52. Oral Fluid vs. Urine Analysis to Monitor Synthetic Cannabinoids and Classic Drugs Recent Exposure.
Blandino V; Wetzel J; Kim J; Haxhi P; Curtis R; Concheiro M
Curr Pharm Biotechnol; 2017; 18(10):796-805. PubMed ID: 29173162
[TBL] [Abstract][Full Text] [Related]
53. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
[TBL] [Abstract][Full Text] [Related]
54. Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine.
Hofer KE; Degrandi C; Müller DM; Zürrer-Härdi U; Wahl S; Rauber-Lüthy C; Ceschi A
Clin Toxicol (Phila); 2014 Dec; 52(10):1288-91. PubMed ID: 25350467
[TBL] [Abstract][Full Text] [Related]
55. Ischemic stroke associated with the use of a synthetic cannabinoid (spice).
Moeller S; Lücke C; Struffert T; Schwarze B; Gerner ST; Schwab S; Köhrmann M; Machold K; Philipsen A; Müller HH
Asian J Psychiatr; 2017 Feb; 25():127-130. PubMed ID: 28262132
[TBL] [Abstract][Full Text] [Related]
56. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
King A; Hill SL; Pucci M; Bailey G; Keating L; Macfarlane R; Cantle F; Hudson S; Thomas SHL
Clin Toxicol (Phila); 2022 Oct; 60(10):1094-1098. PubMed ID: 35943421
[TBL] [Abstract][Full Text] [Related]
57. Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids.
Vučinić S; Kilibarda V; Đorđević S; Đorđević D; Perković-Vukčević N; Vuković-Ercegović G; Antonijević B; Ćurčić M; Antonijević E; Brajković G
Arh Hig Rada Toksikol; 2018 Jun; 69(2):178-185. PubMed ID: 29990297
[TBL] [Abstract][Full Text] [Related]
58. AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema.
Maeda H; Kikura-Hanajiri R; Kawamura M; Nagashima E; Yoshida KI
Clin Toxicol (Phila); 2018 Feb; 56(2):143-145. PubMed ID: 28707493
[TBL] [Abstract][Full Text] [Related]
59. Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA.
Choi H; Kim S; Jang H; Kim HJ; Choe S
Forensic Sci Int; 2022 Sep; 338():111385. PubMed ID: 35863161
[TBL] [Abstract][Full Text] [Related]
60. Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project.
Bäckberg M; Beck O; Helander A
Clin Toxicol (Phila); 2015 Nov; 53(9):856-64. PubMed ID: 26295489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
